News | December 04, 2025
Philips unveils helium-free 3.0T MRI innovation at RSNA 2025
The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology
The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
The PCR-based test, delivered via Roche’s cobas liat system, allows results to be obtained during a patient consultation in GP practices and Emergency Rooms
Here's a development that aims to keep your blood pressure in check. Literally!
The company is excluding data from the affected sites to maintain the study's integrity
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
Subscribe To Our Newsletter & Stay Updated
